Cargando…
Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
INTRODUCTION: Primary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease may have different long-term outcomes. After 10 years of follow-up, 35%–50% of the untreated patients with persistent nephrotic syndrome may die or progress to end stage renal disease. Th...
Autores principales: | Scolari, Francesco, Dallera, Nadia, Gesualdo, Loreto, Santoro, Domenico, Pani, Antonello, Santostefano, Marisa, Feriozzi, Sandro, Mani, Laila-Yasmin, Boscutti, Giuliano, Messa, Piergiorgio, Magistroni, Riccardo, Quaglia, Marco, Ponticelli, Claudio, Ravani, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924835/ https://www.ncbi.nlm.nih.gov/pubmed/31806605 http://dx.doi.org/10.1136/bmjopen-2019-029232 |
Ejemplares similares
-
Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016) -
A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study
por: Rojas-Rivera, Jorge, et al.
Publicado: (2015) -
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023) -
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020) -
Cyclophosphamide/rituximab: COVID-19 infection: case report
Publicado: (2021)